Deals, Mergers and Acquisitions, and Licensing - Pharmaceutical Executive


Mergers, acquisitions, strategic partnerships, and product licensing. Plus, strategies and tactics for better deal-making

Big Deals

February 1, 2008

Many say licensing is the new R&D. We've rounded up the unions to watch from the third quarter of 2007.

GSK to Pay $1 Billion for Synta Melanoma Drug

October 17, 2007

In a blockbuster codevelopment deal, GlaxoSmithKline gains rights to an innovative Phase III melanoma drug.

M&A: Panning for Gold

September 1, 2007

here's a solid case to be made for choosing A. The market for deals has been robust through the first half of 2007. A Cowen research report counted 10 public deals done by July 2007, compared with 14 for all of 2006. Another data source, Irving Levin Associates, cites 455 public and private healthcare deals in the first six months of 2007, a 12 percent decrease from the same period last year—but an 18 percent rise in deal value.

Novartis to Intercell: "Gimme All Your Vax."

July 11, 2007

But is the pharma-biotech vaccine deal a prelude to a takeover?

Roche to Ventana: "Let's Make A Deal"

July 11, 2007

...And the spurned suitor won't take "No" for an answer

Actavis Going Private?

July 3, 2007

The month in deals: Merck KGaA's generics unit goes to Mylan; Genzyme acquires its partner in a key oncology drug; and Amgen makes significant acquisitions in kidney disease and diabetes/inflammatory diseases

A Very Specialty Moment

June 1, 2007

While the most sought-after opinion leaders are often older, well-established physicians, companies should also be aware of the rising stars. Younger, up-and-coming specialists who are beginning to publish are often more cutting-edge and open to experimental approaches.

Biotech, The Incredible Swelling Industry

May 2, 2007

New report names 2006 'year of the deal.'

AstraZeneca Serious, 'Not Desperate,' in MedImmune Deal

May 2, 2007

Pricey merger adds expertise in vaccines, biologics.


Click here